These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 11943448)
21. Interleukin-2 in clinical trials: other factors to be considered. Nannini EC J Infect Dis; 2001 Feb; 183(4):679-80. PubMed ID: 11170999 [No Abstract] [Full Text] [Related]
22. The use of interleukin-2 in human immunodeficiency virus infection. Anaya JP; Sias JJ Pharmacotherapy; 2005 Jan; 25(1):86-95. PubMed ID: 15767224 [TBL] [Abstract][Full Text] [Related]
23. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571 [TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439 [TBL] [Abstract][Full Text] [Related]
25. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R; J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338 [TBL] [Abstract][Full Text] [Related]
30. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Siegfried N; van der Merwe L; Brocklehurst P; Sint TT Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. Kahn JO; Cherng DW; Mayer K; Murray H; Lagakos S JAMA; 2000 Nov; 284(17):2193-202. PubMed ID: 11056590 [TBL] [Abstract][Full Text] [Related]
32. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial). Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540 [TBL] [Abstract][Full Text] [Related]
33. Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial. Tavel JA; Fosdick L; Control Clin Trials; 2001 Feb; 22(1):42-8. PubMed ID: 11165422 [TBL] [Abstract][Full Text] [Related]
34. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042. Bartlett JA; Berend C; Petroni GR; Ottinger J; Tyler DL; Pettinelli C; Weinhold KJ J Infect Dis; 1998 Oct; 178(4):1170-3. PubMed ID: 9806053 [TBL] [Abstract][Full Text] [Related]
35. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018 [TBL] [Abstract][Full Text] [Related]
36. Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. Lifson AR; Rhame FS; Belloso WH; Dragsted UB; El-Sadr WM; Gatell JM; Hoy JF; Krum EA; Nelson R; Pedersen C; Pett SL; Davey RT HIV Clin Trials; 2006; 7(3):125-41. PubMed ID: 16880169 [TBL] [Abstract][Full Text] [Related]
37. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects. Larsen CS; Ostergård L; Møller BK; Buhl MR Scand J Infect Dis; 2000; 32(2):153-60. PubMed ID: 10826900 [TBL] [Abstract][Full Text] [Related]
38. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499 [TBL] [Abstract][Full Text] [Related]
39. IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort. Fontas E; Kousignian I; Pradier C; Poizot-Martin I; Durier C; Weiss L; Levy Y; Costagliola D; ; J Antimicrob Chemother; 2010 Oct; 65(10):2215-23. PubMed ID: 20702463 [TBL] [Abstract][Full Text] [Related]